Multiple myeloma (MM) is a genetically complex disease that evolves from pre-malignant
stages, such as monoclonal gammaopathy of undetermined significance and smouldering …

The diagnosis and treatment of multiple myeloma has changed dramatically in the past
decade. The disease definition has been updated to include highly specific biomarkers in …

Abstract The International Myeloma Working Group consensus updates the definition for
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …

Multiple myeloma accounts for approximately 10% of hematologic malignancies. The
diagnosis requires≥ 10% clonal bone marrow plasma cells or a biopsy proven …

In multiple myeloma malignant plasma cells expand within the bone marrow. Since this site
is well-perfused, a rapid dissemination of “fitter” clones may be anticipated. However, an …

Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 2% of all haematological
malignancies and predominantly affects older individuals (with a median age at diagnosis of …

Therapy for multiple myeloma (MM) has markedly changed in the past decade with the
introduction of new drugs, but it is not clear whether the improvements have been sustained …

Substantial improvements in survival have been seen in multiple myeloma (MM) over recent
years, associated with the introduction and widespread use of multiple novel agents and …

Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. SMM
is distinguished from monoclonal gammopathy of undetermined significance by a much …

The interpretation of cytogenetic abnormalities in multiple myeloma (MM) is often a
challenging task. MM is characterized by several cytogenetic abnormalities that occur at …